Triple

T1169405
Position Surface form Disambiguated ID Type / Status
Subject Spinraza E24879 entity
Predicate hasInternationalNonproprietaryName P24556 FINISHED
Object nusinersen E24879 NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: nusinersen | Statement: [Spinraza, hasInternationalNonproprietaryName, nusinersen]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: nusinersen
Context triple: [Spinraza, hasInternationalNonproprietaryName, nusinersen]
  • A. Spinraza chosen
    Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
  • B. onasemnogene abeparvovec
    Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
  • C. Aduhelm
    Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
  • D. riluzole
    Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
  • E. Ionis Pharmaceuticals
    Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07 
Target predicate: hasInternationalNonproprietaryName
Context triple: [Spinraza, hasInternationalNonproprietaryName, nusinersen]
  • A. hasEnglishName
    Indicates that an entity is associated with a name expressed in the English language.
  • B. hasInternationalVersion
    Indicates that an entity has a corresponding version or counterpart adapted for use in multiple countries or international contexts.
  • C. hasLatinName
    Indicates that an entity is associated with a specific Latin (scientific) name.
  • D. hasTraditionalName
    Indicates that an entity is associated with a name traditionally used or recognized for it, often rooted in long-standing cultural or historical practice.
  • E. isInternational
    Indicates that something has a connection to, involves, or extends across more than one country.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a494082a7c819095004f423f294a64 completed March 1, 2026, 7:31 p.m.
NER Named-entity recognition batch_69a4bce821b481908bc278a3fa7973f4 completed March 1, 2026, 10:25 p.m.
NED1 Entity disambiguation (via context triple) batch_69ac6f17aa608190920b7df62b8dd903 completed March 7, 2026, 6:31 p.m.
PD Predicate disambiguation batch_69a4bb5656948190b0b1d5446ad06005 completed March 1, 2026, 10:19 p.m.
PDg Predicate description generation batch_69a4bbd7ff1881908c943ecdfea59e81 completed March 1, 2026, 10:21 p.m.
Created at: March 1, 2026, 7:45 p.m.